HC Wainwright Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

Key Points

• HC Wainwright has raised its price target for United Therapeutics from $400.00 to $500.00, indicating a potential upside of 31.42% from the current stock price.
• United Therapeutics reported a quarterly earnings miss of $6.41 per share, below the consensus estimate of $6.80, despite an 11.7% year-over-year revenue increase.
• Recent insider activity includes significant stock sales, with directors reducing their holdings, while institutional investments in the company have increased, showcasing mixed signals about future performance.

United Therapeutics (NASDAQ:UTHR - Free Report) had its price target hoisted by HC Wainwright from $400.00 to $500.00 in a research report report published on Friday, MarketBeat reports. HC Wainwright currently has a buy rating on the biotechnology company's stock. HC Wainwright also issued estimates for United Therapeutics' FY2027 earnings at $28.37 EPS.

A number of other research analysts have also recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company lifted their price objective on United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday, September 3rd. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, Jefferies Financial Group lifted their price objective on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $429.62.

United Therapeutics Trading Down 1.5%

Shares of UTHR stock traded down $5.90 during mid-day trading on Friday, reaching $394.62. The stock had a trading volume of 623,780 shares, compared to its average volume of 865,507. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $436.95. The company has a market cap of $17.80 billion, a P/E ratio of 15.40, a price-to-earnings-growth ratio of 6.11 and a beta of 0.62. The business has a 50-day simple moving average of $309.83 and a 200 day simple moving average of $305.60.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the business earned $5.85 EPS. The company's quarterly revenue was up 11.7% compared to the same quarter last year. Research analysts anticipate that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 106,181 shares of company stock worth $35,537,239. Company insiders own 10.30% of the company's stock.

Institutional Trading of United Therapeutics

Institutional investors have recently modified their holdings of the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the 2nd quarter worth approximately $29,000. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics during the 1st quarter worth approximately $32,000. Finally, Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.